Search research articles
Contact Us
Filters
Showing results (41-50 of 111) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2005
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis
David V Gold, David E Modrak, Zhiliang Ying, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 11, 2017
Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in <i>BRCA1/2</i>-wild-type Triple-Negative Breast Cancer
Thomas M Cardillo, Robert M Sharkey, Diane L Rossi, et al.
Molecular Cancer Therapeutics
|
February 22, 2013
Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers
Serengulam V Govindan, Thomas M Cardillo, Robert M Sharkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2007
Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update
Robert M Sharkey, Habibe Karacay, William J McBride, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 26, 2006
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting
Edmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Cancer Research
|
July 3, 2008
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody
Robert M Sharkey, Habibe Karacay, Samuel Litwin, et al.
Cancer Research
|
January 25, 2003
A universal pretargeting system for cancer detection and therapy using bispecific antibody
Robert M Sharkey, William J McBride, Habibe Karacay, et al.
Gynecologic Oncology Reports
|
July 7, 2018
Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
Chanhee Han, Stefania Bellone, Peter E Schwartz, et al.
Molecular Pharmaceutics
|
November 18, 2014
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug
Serengulam V Govindan, Thomas M Cardillo, Edmund A Rossi, et al.
Bioconjugate Chemistry
|
June 15, 2010
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex
William J McBride, Christopher A D'Souza, Robert M Sharkey, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 111) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 14, 2005
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis
David V Gold, David E Modrak, Zhiliang Ying, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 11, 2017
Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in <i>BRCA1/2</i>-wild-type Triple-Negative Breast Cancer
Thomas M Cardillo, Robert M Sharkey, Diane L Rossi, et al.
Molecular Cancer Therapeutics
|
February 22, 2013
Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers
Serengulam V Govindan, Thomas M Cardillo, Robert M Sharkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2007
Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update
Robert M Sharkey, Habibe Karacay, William J McBride, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 26, 2006
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting
Edmund A Rossi, David M Goldenberg, Thomas M Cardillo, et al.
Cancer Research
|
July 3, 2008
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody
Robert M Sharkey, Habibe Karacay, Samuel Litwin, et al.
Cancer Research
|
January 25, 2003
A universal pretargeting system for cancer detection and therapy using bispecific antibody
Robert M Sharkey, William J McBride, Habibe Karacay, et al.
Gynecologic Oncology Reports
|
July 7, 2018
Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
Chanhee Han, Stefania Bellone, Peter E Schwartz, et al.
Molecular Pharmaceutics
|
November 18, 2014
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug
Serengulam V Govindan, Thomas M Cardillo, Edmund A Rossi, et al.
Bioconjugate Chemistry
|
June 15, 2010
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex
William J McBride, Christopher A D'Souza, Robert M Sharkey, et al.
Page
of 12